These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 26728536)
1. [Newly developed drugs to improve bone strength]. Hagino H Clin Calcium; 2016 Jan; 26(1):99-105. PubMed ID: 26728536 [TBL] [Abstract][Full Text] [Related]
2. Novel approaches to the treatment of osteoporosis. Appelman-Dijkstra NM; Papapoulos SE Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):843-57. PubMed ID: 25432356 [TBL] [Abstract][Full Text] [Related]
3. The future of osteoporosis treatment - a research update. Lippuner K Swiss Med Wkly; 2012; 142():w13624. PubMed ID: 22815185 [TBL] [Abstract][Full Text] [Related]
4. New approaches to the treatment of osteoporosis. Silva BC; Bilezikian JP Annu Rev Med; 2011; 62():307-22. PubMed ID: 21054170 [TBL] [Abstract][Full Text] [Related]
5. [Assessment of bone quality. Drug developments for restoring bone mass and quality in the treatment of osteoporosis]. Nakamura T Clin Calcium; 2008 Mar; 18(3):374-80. PubMed ID: 18310826 [TBL] [Abstract][Full Text] [Related]
6. Odanacatib for the treatment of osteoporosis. Boggild MK; Gajic-Veljanoski O; McDonald-Blumer H; Ridout R; Tile L; Josse R; Cheung AM Expert Opin Pharmacother; 2015; 16(11):1717-26. PubMed ID: 26149759 [TBL] [Abstract][Full Text] [Related]
7. [Osteoanabolics and the forthcoming drugs for the treatment of osteoporosis]. Grazio S Reumatizam; 2014; 61(2):95-9. PubMed ID: 25427402 [TBL] [Abstract][Full Text] [Related]
8. Cathepsin K inhibitors and antisclerostin antibodies. The next treatments for osteoporosis? Chapurlat R Joint Bone Spine; 2016 May; 83(3):254-6. PubMed ID: 26919802 [No Abstract] [Full Text] [Related]
11. Sclerostin: how human mutations have helped reveal a new target for the treatment of osteoporosis. Robinson MK; Caminis J; Brunkow ME Drug Discov Today; 2013 Jul; 18(13-14):637-43. PubMed ID: 23579167 [TBL] [Abstract][Full Text] [Related]
12. Osteoporosis: now and the future. Rachner TD; Khosla S; Hofbauer LC Lancet; 2011 Apr; 377(9773):1276-87. PubMed ID: 21450337 [TBL] [Abstract][Full Text] [Related]
14. [Monoclonal antibodies to sclerostin for the treatment of osteoporosis]. Soen S Clin Calcium; 2013 Jun; 23(6):884-9. PubMed ID: 23719502 [TBL] [Abstract][Full Text] [Related]
15. [Perspective for development of parathyroid hormone and related compounds as therapeutic agents for osteoporosis]. Ikeda K; Fukagawa M Nihon Rinsho; 2005 Oct; 63 Suppl 10():367-71. PubMed ID: 16279664 [No Abstract] [Full Text] [Related]
16. Future directions for new medical entities in osteoporosis. Ferrari S Best Pract Res Clin Endocrinol Metab; 2014 Dec; 28(6):859-70. PubMed ID: 25432357 [TBL] [Abstract][Full Text] [Related]
17. Current Status of Bone-Forming Therapies for the Management of Osteoporosis. Sølling ASK; Harsløf T; Langdahl B Drugs Aging; 2019 Jul; 36(7):625-638. PubMed ID: 31066015 [TBL] [Abstract][Full Text] [Related]
18. The relative merits of anabolics versus anti-resorptive compounds: where our targets should be, and whether we are addressing them. Gasser JA Curr Opin Pharmacol; 2006 Jun; 6(3):313-8. PubMed ID: 16650802 [TBL] [Abstract][Full Text] [Related]
19. [Mechanisms of action of anticatabolic drugs used in osteoporosis therapy]. Kryśkiewicz E; Lorenc RS Endokrynol Pol; 2009; 60(2):134-44. PubMed ID: 19396757 [TBL] [Abstract][Full Text] [Related]
20. New therapeutics for osteoporosis. Ng KW; Martin TJ Curr Opin Pharmacol; 2014 Jun; 16():58-63. PubMed ID: 24699340 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]